Think FASTER and Remember MORE… GUARANTEED!!!

3-in-1 Brain Memory Supplement Super-Formula for Cognition, Memory, and Focus


* As an introduction to our remarkably-effective products, receive an extra month supply – on us! Offer applies to all First-Time Buyers only (substitute bottles for Mood or Protection available upon request). 

Click “ADD-TO-CART” to get your Brain Memory Supplements, and receive a FREE BOTTLE with your order!

You’re guaranteed to feel dramatic results with our Brain Memory Supplements or your money-back!

Click to ORDER Memory Supplement



Amazing New Memory Supplement is a Powerful 3-in-1 Formula for Incredible Improvement in Cognition, Memory, and Focus!

Our Mental Capacity Is At Risk without Memory Supplements!

If you are 35 or older you probably are experiencing some of the effects of reduced brain function, that’s not uncommon. Studies show that as we age, we can lose up to 7% of our brain mass. That is a lot! This results in regions of our brain that our responsible for memory, and for processing speed, to deteriorate. Additionally, there is further reduction of our mental capacity as we age, due to poor absorption of brain-enhancing foods and in decreased blood circulation to the brain. Is a SUPERIOR Memory Supplement the answer?

Fight Back with Superior Brain Nutrition!

It’s a little scary, but there is a solution for memory concerns. There are some exciting new nutrients that have been show to have dramatic effects on the brain and its various capabilities, including memory. TOTAL PERFORMANCE™ from brainALIVE has taken the best of these nutrients and combined them to produce an incredible 3-in-1 memory supplement formula that will help your brain to be its best. No need to look elsewhere only to find memory supplements of lesser quality or inferior-grade supplements.




Why buy 3 different memory supplement formulas when you can get it all in 1 Super-Formula, with TOTAL PERFORMANCE™?!

Many memory supplement formulations only address one (or two, at best, but not usually very well). Contrast that with TOTAL PERFORMANCE™ memory supplements that uses the most dynamic ingredients in significant levels. These levels in a supplement formula for Memory needs to address all three of the major areas of a high-functioning brain: Memory, Focus, and Cognition. A memory supplement that fails to address ALL of these MAJOR areas for concern in memory performance, cannot truly be called an effective MEMORY SUPPLEMENT.



You would typically pay 3 times as much to get these incredible benefits from any host of products that claim they can supplement brain memory needs!


You CAN’T get FIND what we offer ANYWHERE else!! Our Memory Supplement is the CHOICE you should MAKE to get results that WILL improve your memory without the need of so many other ineffective supplements.




YOU get it all in our ONE bottle

Don’t wait!!






These are the SUPERIOR ingredients at work
FOR YOU in our Memory Supplement SUPER FORMULA…


checkmarkEnhanced Memory

Decline in the ability of memory (especially short-term) is often related to a decline in the neurotransmitter Acetylcholine. To increase memory, you have to intake nutrients, which both increase acetylcholine and limit the enzyme that breaks acetylcholine down. TOTAL PERFORMANCE is the supplement formula suited for those Memory needs.


checkmarkImproved Focus

Lack of mental focus is often attributed to insufficient levels of the neurotransmitter norepinephrine and to poor blood circulation in the brain. Our formula focuses on these needs as a superior supplement. The focus will make for a great memory.


checkmarkCognition (information processing)Decline in cognitive function, such as processing speed and overall performance is correlated to a number of factors such as nerve transmission, levels of the neurotransmitter dopamine, and even to total brain mass. You can’t miss this need when it comes to finding an effective solution to your memory supplement need.






Don’t wait any longer!


You can fight brain aging and improve your memory, focus, and cognition now. You have nothing to lose and EVERYTHING to gain with this amazing, new memory supplement!



Take advantage of this incredible, limited-time, first-time buyer offer:

Buy TOTAL PERFORMANCE™ memory supplements and get a FREE Bottle of DHA Protect™ for the Ultimate Brain Performance System!





• Total Performance™ 3-in-1 Super-Formula

• DHA Protect™







DON’T WAIT any longer!


You can fight brain aging and improve your memory, focus, and cognition now.


You have nothing to lose and YOUR HEALTH to gain!







Bonavita, E. (1986). “[Neuropsychological study of the senile brain during and after single and combined treatment with deanol and citicoline].” Clin Ter 117(5): 387-98.
Ceder, G., et al. Effects of 2-Dimethylaminoethanol (DMAE) on the metabolism of choline in plasma. Journal of Neurochemistry. 30:1293-1296, 1978.
Coleman, N., et al. DMAE in the treatment of hyperactive children. Psychosomatics. 17:68-72, 1976.
Ferris, S. H., G. Sathananthan, S. Gershon and C. Clark (1977). “Senile dementia: treatment with deanol.” J Am Geriatr Soc 25(6): 241-4.
Fisman, M., H. Mersky and E. Helmes (1981). “Double-blind trial of 2-dimethylaminoethanol in Alzheimer’s disease.” Am J Psychiatry 138(7): 970-2.
Knoble, M. 2-Dimethylaminoethanol (DMAE) in behavior problems of children. Science Medicine (Buenos Aries). 119:939-944, 1961.
Knusel, B., D. J. Jenden, S. D. Lauretz, R. A. Booth, K. M. Rice, M. Roch and J. J. Waite (1990). “Global in vivo replacement of choline by N-aminodeanol. Testing a hypothesis about progressive degenerative dementia: I. Dynamics of choline replacement.” Pharmacol Biochem Behav 37(4): 799-809.
Lewis, J. A., et al. DMAE and methylpheni date in minimal brain dysfunction. Clin Pharmacol Ther. 17:534-540, 1975.
Lewis, J. A. and B. S. Lewis (1977). “Deanol in minimal brain dysfunction.” Dis Nerv Syst 38(12 Pt 2): 21-4.
Marsh, G. R. and M. Linnoila (1979). “The effects of deanol on cognitive performance and electrophysiology in elderly humans.” Psychopharmacology 66(1): 99-104.
Murphree, H. B., et al. The stimulant effect of 2-diethylaminoethanol (DMAE) in human volunteer subjects. Clinical Pharmacology and Therapeutics. 1:303-310, 1960.
Oettinger, L. The use of DMAE in the treatment of disorders of behavior in children. Journal of Pediatrics. 53:671-675, 1958.
Pfeiffer, C. C. Parasympathetic neurohumors. Possible precursors and effect on behavior. International Review of Neurobiology. 1959:195-244.
Pfeiffer, C., et al. Stimulant effect of 2-Dimethyl-l-aminoethanol (DMAE): Possible precursor of brain acetylcholine. Science. 126:610-611, 1957.
Rosenberg, G. S., et al. The use of cholinergic precursors in neuropsychiatric diseases. American Journal of Clinical Nutrition. 36:709-720, 1982.
Russell, R. W., D. J. Jenden, R. A. Booth, S. D. Lauretz, K. M. Rice and M. Roch (1990). “Global in vivo replacement of choline by N-aminodeanol. Testing a hypothesis about progressive degenerative dementia: II. Physiological and behavioral effects.” Pharmacol Biochem Behav 37(4): 811-20.
Zs-Nagy, I., et al. On the role of cross-linking of cellular proteins in aging. Mech Aging Dev. 14:245-251, 1980.
Cheng DH, Ren H, Tang XC. Huperzine A, a novel promising acetylcholinesterase inhibitor. Neuroreport. 1996; 8:97-101.
(He XC, Yu GL, Bai DL. Studies on analogues of huperzine A for treatment of senile dementia. VI. Asymmetric total synthesis of 14-nor-huperzine A and its inhibitory activity of acetylcholinesterase. [Article in Chinese] Yao Xue Xue Bao. 2003;38(5):346-349).
Xu SS, Gao ZX, Weng Z, et al. Efficacy of tablet huperzine-A on memory, cognition and behavior in Alzheimer’s disease. Chung Kuo Yao Li Hsueh Pao. 1995; 16:391-395.
Grunwald, J., Raveh, L., Doctor, BP. et al (1994) Huperzine A as a pretreatment candidate drug against nerve agent toxicity. Life Sci 54: 991-997.
Hanin, I., Tang, XC., Kindel, GL. et al (1993) Natural and synthetic Huperzine A: effect on cholinergic function in vitro and in vivo. Ann N Y Acad Sci 695:304-306.
Xu SS, Cai ZY, Qu ZW, Yang RM, Cai YL, Wang GQ, Su XQ, Zhong XS, Cheng RY, Xu WA, Li JX, Feng B. Huperzine-A in capsules and tablets for treating patients with Alzheimer’s disease. Acta Pharmacol Sin 1999 Jun;20(6):486-90.
Stough C, Lloyd J, Clarke J, et al. The chronic effects of an extract of Bacopa monniera (Brahmi) on cognitive function in healthy human subjects. Psychopharmacology 2001;156:481-4.
Sharma R, Chaturvedi C, Tewari PV. Efficacy of Bacopa monnieri in revitalizing intellectual functions in children. J Res Edu Indian Med 1987;Jan-June:1-12.
Negi KS, Singh YD, Kushwaha KP, et al. Clinical evaluation of memory enhancing properties of Memory Plus in children with attention deficit hyperactivity disorder. Ind J Psychiatry 2000;42:Supplement.
Singh RH, Singh L. Studies on the anti-anxiety effect of the Medyha Rasayana drug, Brahmi (Bacopa monniera Wettst.)–Part 1. J Res Ayur Siddha 1980;1:133-148.
Bhattacharya SK, Ghosal S. Anxiolytic activity of a standardized extract of Bacopa monniera in an experimental study. Phytomedicine 1998;5:77-82.
McDaniel MA, Maier SF, Einstein GO (2003). “‘Brain-specific’ nutrients: a memory cure?”. Nutrition 19 (11-12): 957–75. doi:10.1016/S0899-9007(03)00024-8. PMID 14624946.
Szatmari SZ, Whitehouse PJ (2003). Szatmári, Szabolcs. ed. “Vinpocetine for cognitive impairment and dementia”. Cochrane Database of Systematic Reviews (1): CD003119. doi:10.1002/14651858.CD003119. PMID 12535455.
Subhan Z, Hindmarch I (1985). “Psychopharmacological effects of vinpocetine in normal healthy volunteers”. European Journal of Clinical Pharmacology 28 (5): 567–71. doi:10.1007/BF00544068.
Red blood cell omega-3 fatty acid levels and markers of accelerated brain aging.
Tan ZS, Harris WS, Beiser AS, Au R, Himali JJ, Debette S, Pikula A, Decarli C, Wolf PA, Vasan RS, Robins SJ, Seshadri S. Neurology. 2012 Feb 28;78(9):658-64.
Effects of large doses of arachidonic Acid added to docosahexaenoic Acid on social impairment in individuals with autism spectrum disorders: a double-blind, placebo-controlled, randomized trial. Yui K, Koshiba M, Nakamura S, Kobayashi Y.
J Clin Psychopharmacol. 2012 Apr;32(2):200-6.
Effects of a diet integration with an oily emulsion of DHA-phospholipids containing melatonin and tryptophan in elderly patients suffering from mild cognitive impairment.
Mariangela R, Annalisa O, Milena F, Marco M, Neldo A, Roberta C, Rita S, Renata C, Enzo G, Benvenuto C. Nutr Neurosci. 2011 Dec 20. [Epub ahead of print]
Plasma and Brain Fatty Acid Profiles in Mild Cognitive Impairment and Alzheimer’s Disease. Cunnane SC, Schneider JA, Tangney C, Tremblay-Mercier J, Fortier M, Bennett DA, Morris MC. J Alzheimers Dis. 2012 Jan 20. [Epub ahead of print]
Docosahexaenoic Acid (DHA): An Ancient Nutrient for the Modern Human Brain.
Bradbury J. Nutrients. 2011 May;3(5):529-54. Epub 2011 May 10.
Weinmann, S; Roll, S; Schwarzbach, C; Vauth, C; Willich, SN (2010). “Effects of Ginkgo biloba in dementia: systematic review and meta-analysis”. BMC geriatrics 10: 14. doi:10.1186/1471-2318-10-14. PMC 2846949. PMID 20236541.
Dekosky, S. T.; Williamson, J. D.; Fitzpatrick, A. L.; Kronmal, R. A.; Ives, D. G.; Saxton, J. A.; Lopez, O. L.; Burke, G. et al (2008). “Ginkgo biloba for Prevention of Dementia: A Randomized Controlled Trial”. JAMA: the Journal of the American Medical Association 300 (19): 2253–62. doi:10.1001/jama.2008.683. PMC 2823569. PMID 19017911.
Snitz, B. E.; O’Meara, E. S.; Carlson, M. C.; Arnold, A. M.; Ives, D. G.; Rapp, S. R.; Saxton, J.; Lopez, O. L. et al (2009). “Ginkgo biloba for Preventing Cognitive Decline in Older Adults: A Randomized Trial”. JAMA: the Journal of the American Medical Association 302 (24): 2663–70. doi:10.1001/jama.2009.1913.
Elsabagh, Sarah; Hartley, David E.; Ali, Osama; Williamson, Elizabeth M.; File, Sandra E. (2005). “Differential cognitive effects of Ginkgo biloba after acute and chronic treatment in healthy young volunteers”. Psychopharmacology 179 (2): 437–46. doi:10.1007/s00213-005-2206-6. PMID 15739076.
Kennedy, David O.; Scholey, Andrew B.; Wesnes, Keith A. (2000). “The dose-dependent cognitive effects of acute administration of Ginkgo biloba to healthy young volunteers”. Psychopharmacology 151 (4): 416–23. doi:10.1007/s002130000501. PMID 11026748.
Fehske, Christian J.; Leuner, Kristina; Müller, Walter E. (2009). “Ginkgo biloba extract (EGb761®) influences monoaminergic neurotransmission via inhibition of NE uptake, but not MAO activity after chronic treatment”. Pharmacological Research 60 (1): 68–73. doi:10.1016/j.phrs.2009.02.012. PMID 19427589.
Ginkgo Extract Has Multiple Actions on Alzheimer Symptoms Newswise, Retrieved on August 25, 2008.
Mazza, M.; Capuano, A.; Bria, P.; Mazza, S. (2006). “Ginkgo biloba and donepezil: a comparison in the treatment of Alzheimer’s dementia in a randomized placebo-controlled double-blind study”. European Journal of Neurology 13 (9): 981–5. doi:10.1111/j.1468-1331.2006.01409.x. PMID 16930364.
McCarney R, Fisher P, Iliffe S, van Haselen R, Griffin M, van der Meulen J, Warner J (2008). “Ginkgo biloba for mild to moderate dementia in a community setting: a pragmatic, randomised, parallel-group, double-blind, placebo-controlled trial”. Int J Geriatr Psychiatry 23 (12): 1222–30. doi:10.1002/gps.2055. PMID 18537221.
“Ginkgo ‘does not treat dementia’”. BBC News. June 16, 2008.
Ihl R, Bachinskaya N, Korczyn AD, Vakhapova V, Tribanek M, Hoerr R, Napryeyenko O (2010). “Efficacy and safety of a once-daily formulation of Ginkgo biloba extract EGb 761 in dementia with neuropsychiatric features: a randomized controlled trial”. Int J Geriatr Psychiatry: n/a. doi:10.1002/gps.2662. PMID 21140383.
Smith, P; MacLennan, K; Darlington, CL (1996). “The neuroprotective properties of the Ginkgo biloba leaf: a review of the possible relationship to platelet-activating factor (PAF)”. Journal of Ethnopharmacology 50 (3): 131–9. doi:10.1016/0378-8741(96)01379-7. PMID 8691847.
Klinkhammer P, Szelies B, Heiss WD. Effect of phosphatidylserine on cerebral glucose metabolism in Alzheimer’s disease. Dementia. 1990;1(4):197-201.
Funfgeld EW, et al. Double-blind study with phosphatidylserine (PS) in parkinsonian patients with senile dementia of Alzheimer’s type (SDAT). Prog Clin Biol Res 1989;317:1235-46.
Crook T, et al. Effects of Phosphatidylserine in Alzheimer’s Disease. Psychopharmacol Bull 1992;28(1):61-66.
Engel RR, Double-blind cross-over study of phosphatidylserine vs. placebo in patients with early dementia of the Alzheimer type. Eur Neuropsychopharmacol 1992 Jun;2(2):149-55.
T.H. Crook.Treatment of Age-Related Cognitive Decline: Effects of Phosphatidylserine in Anti-Aging 33 Medical Therapeutics,Vol II, edited by R.M. Klatz, Health Quest Publications, Chicago, 1998, 20 – 29.
F. Casamenti, C. Scali, G. Pepeu. Phosphatidylserine reverses the age-dependent decrease in cortical acetylcholine release: a microdialysis study, Eur. J. Pharmacol 1991, 194, 11 – 16.
S.Mazzari, A. Battistella. Phosphatidylserine effects on dopamine release from striatum synaptosomes. In: Multidisciplinary Approach to Brain Development. C. Benedetta, R. Balazs, G. Gombos, G. Porcellani (Eds.). Elsevier/North Holland, Amsterdam, 1980, 569 – 570.
G. Calderoni, F. Aporti, F. Bellini, A.C. Sonetti, R. Rubini, S.Telato, C. Xu, A. Canotti, G.Toffano. Phospholipids as pharmacological tools in the aging brain. In: L.A.Horrocks, J.N. Kanfer, G. Porcellati (eds). Phospholipids in the nervous system,Vol II, Physiological roles. Raven Press, New York, 1985, 11 – 19.
F. Casamenti, C. Scali, G. Pepeu. Phosphatidylserine reverses the age-dependent decrease in cortical acetylcholine release: a microdialysis study, Eur. J. Pharmacol 1991, 194, 11 – 16.

Gindin, J., et al. 1990, Effect of Soy Lecithin Phosphatidylserine (PS) Treatment on Daily Functioning and Self-Reported General Condition in Patients with Alzheimer’s Disease, The Geriatric Institute of Education and Research Kaplan Medical Centre, Rehovot, and Hadassah Medical School, Hebrew University of Jerusalem, Israel.


Order Line (24 Hr): 1-888-552-9026

Customer Care Hours: Mon.-Thu. 9am – 9pm EDT, Fri. 9am – 7pm EDT, Sat. 9am – 5pm EDT

31103 Rancho Viejo Road, D2-019, San Juan Capistrano, CA 92675 © 2012 Brain Alive